Provider review
Neo Soma Healthcare review
Prints the step from first month to standing rate, then bills its peptides every four weeks.
A four-week cycle is thirteen charges a year, not twelve, and it is stated on the card rather than hidden.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Neo Soma Healthcare
$199/mo semaglutide after a $99 first month
- Vs median
- $30/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two things here pull in opposite directions and both deserve saying. The good one is the semaglutide card, which prints the introductory price and the standing price in the same sentence. That is rare, and it removes the commonest way a reader on this site ends up surprised, which is finding out the real rate at the second charge rather than the first. The bad one is the cadence on the peptide lines. Sermorelin and NAD+ are both billed every four weeks, stated plainly, and four weeks comes round thirteen times in a year rather than twelve. The figure looks monthly and is not: the same number quoted every four weeks costs roughly nine per cent more over a year than it would per calendar month. Tirzepatide is the gap between the two. It is priced as an initial purchase with nothing beside it saying what the second one costs, so the molecule readers most often move up to is the one whose ongoing price is not printed. No milligram appears against any figure on the site.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the introductory price and the standing rate stated together before you start
- You are buying semaglutide, the one line here whose ongoing cost is fully published
- You want free shipping and unlimited follow-up messaging included
Look elsewhere if
- You are buying tirzepatide. Only the initial purchase is priced
- You are budgeting annually — the peptide lines bill thirteen times a year, not twelve
- You want a dose behind the figure. None is published for any line
What it actually costs
Price as published
★ Semaglutide with B12 is quoted as "$99 for your first month, $199/month thereafter" — the intro and the standing rate on one line, which is the honest version of a structure most sellers split across two pages · tirzepatide with glycine and B12 is quoted only as "Initial Purchase: $330" with no standing rate printed beside it, so the two molecules are disclosed to different depths on the same site · AND THE PEPTIDE LINES ARE NOT MONTHLY: sermorelin is "$179 every 4 weeks" and NAD+ is "$175 every 4 weeks" · four weeks recurs 13.04 times a year, not 12, so those figures are about 8.7% dearer per year than the same number would be per calendar month · a men's blend is listed at "$164/month", genuinely monthly · no dose is published for any line
- Vs median
- $30/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. No low-dose product and no dose published, but the disclosure is better than most here in one respect and worse in another. Better: the semaglutide card prints the introductory price and the standing rate in the same sentence, which removes the commonest way a reader is surprised at the second charge. Worse: tirzepatide carries an initial-purchase figure with no standing rate beside it. AND THE PEPTIDE LINES ARE BILLED EVERY FOUR WEEKS, stated openly — thirteen charges a year rather than twelve, so the same figure costs about 8.7% more annually than a calendar month would.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Prints the first-month price and the standing rate together on the semaglutide card.
- States the four-week billing cadence on the peptide cards rather than hiding it.
- Free shipping and unlimited follow-up messaging are listed as included.
Pharmacy, labs and oversight
Neo Soma Healthcare does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What Neo Soma Healthcare publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two things on this site are worth a reader's attention and they pull in opposite directions. The good one is the semaglutide card, which prints the first-month price and the standing price in the same sentence. That is rare and it removes the single most common way a reader here ends up surprised, which is discovering the real rate at the second charge. The bad one is the cadence. The sermorelin and NAD+ lines are billed every four weeks rather than monthly, stated plainly on the card, and four weeks comes round thirteen times in a year rather than twelve. The number is the same but the year is not: a rate quoted every four weeks costs about 8.7% more annually than the identical figure quoted per calendar month. Tirzepatide is the gap. It is priced as an initial purchase and nothing on the card says what the second one costs, so the molecule this site's readers most often move to is the one whose ongoing price is not printed. No milligram appears against any figure.
The honest cons
Tirzepatide shows an initial purchase price with no standing rate printed beside it.
- The sermorelin and NAD+ lines bill every four weeks, which is thirteen charges a year.
- No dose is published against any figure on the site.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Neo Soma Healthcare is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#295 of 373
Ordered with the companies that pay us first, and Neo Soma Healthcare is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.